# Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

> **NCT06703047** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 180 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** ATRA+pd-1+chemo
- **DRUG:** placebo+PD-1+chemo

## Key facts

- **NCT ID:** NCT06703047
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2029-11-20
- **Final completion:** 2030-10-24
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06703047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06703047, "Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06703047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*